Credit: Pixabay/CC0 Public Domain
New research will be published in the European Congress (Eco 2025Malaga from May 11 to 14 shows that about two-thirds of the SURMOUNT-1 test participants have been less than 5% of the so-called NADIR (or the lowest weight) for two-thirds of the SURMOUNT-1 test participants.
This study is Professor Louis Aronne, co -author of Comprehensive weight management centers, endocrine, diabetes and metabolism, Weill Cornell Medicine, New York, NY, and Indianapolis.
Obesity management is a long -term trip that is expected to change weight. For some patients, the previous NADIR weight can be a focus (and disappointment that cannot be reached again). However, there is no clear literature yet that NADIR weight is clinically related. The post-analysis of Surmount-1 research in three years aimed to evaluate weight recovery from NADIR weight over three years (36 months / 176 weeks).
The original Surmount-1 test has been announced Nejm Participants with obesity for 72 weeks in 2022 showed that the participants who were treated with Tir J Pade of 5 mg, 10 mg or 15 mg had a significant weight and continuous decrease in a week.
This analysis includes 690 TirJ Jade -attached participants (65% female, 35% male) with an average age of 49 years old, an average weight of 107kg and an average BMI of 38.6 kg/m of average BMI.2 Obesity (BMI of more than 30 kg/m) has been treated for three years (more than 75%)2) Or overweight (at least 27 kg/m BMI2) And Precmount-1 studies and lost more than 5% of the reference weight when they reached NADIR weight (lowest weight during treatment).
The weight recovery from NADIR to 176 weeks was defined as a difference in weight reduction rate from the baseline to NADIR and the weight reduction up to 176 shares in the baseline. The weight recovery analysis was calculated as an average between groups and was classified as 5%, 5% to 10% and 10% or more weight retaining.
Analysis showed that the average time for NADIR weight was 22 months (96 weeks). The average weight reduction in NADIR weight was 23.1%. The average weight recovery from NADIR to 176 shares was 3.7%, and the average weight decrease in 690 participants was 19.4% (3.7% minus 3.7%) over 690 participants.
176, 73%, 19%, and 8%of the participants who were treated with 176 weeks, 5 mg of Tirze Pad (227 participants) were recovered from 5%, 5%to 10%, and 10%or more, respectively. Similarly, 65%, 26%, and 9%of the participants treated with Tyrje Pad 10 mg (n = 239) were restored to 5%, 5%to 10%, and 10%at NADIR, respectively.
Tirzepatide 15 mg (n = 224), 73%, 20%, and 7%of the participants who have been treated with NADIR, less than 5%, 5%to 10%and 10%or more, respectively.
The author has not yet been analyzed between men and women, or between older participants and participants.
Dr. Aronne said, “According to this analysis, 70% of the participants treated with Tirzepatide have found that the weight recovery is limited after NADIR or the lowest weight, less than 10% of the participants have recovered more than 10% on NADIR weight.
“Overall, these discoveries have been a relatively stable weight trip for three years in three years and three years in a three -year and three -year study, suggesting that a significant weight has not been recovered.”
Provided by the European Association for Obesity Research
recallThe three -year study of Tirzepatide has been found to recover less than 5% at the lowest weight (2025, April 11), which most patients searched on April 14, 2025.
This document is copyrighted. In addition to fair transactions for individual research or research purposes, you cannot reproduce any part without written permission. The contents are provided only for information purposes.
